193 related articles for article (PubMed ID: 23573299)
1. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.
Oberoi P; Jabulowsky RA; Bähr-Mahmud H; Wels WS
PLoS One; 2013; 8(4):e61267. PubMed ID: 23573299
[TBL] [Abstract][Full Text] [Related]
2. Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.
Jabulowsky RA; Oberoi P; Bähr-Mahmud H; Dälken B; Wels WS
Bioconjug Chem; 2012 Aug; 23(8):1567-76. PubMed ID: 22759275
[TBL] [Abstract][Full Text] [Related]
3. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.
Dälken B; Giesübel U; Knauer SK; Wels WS
Cell Death Differ; 2006 Apr; 13(4):576-85. PubMed ID: 16179940
[TBL] [Abstract][Full Text] [Related]
4. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
[TBL] [Abstract][Full Text] [Related]
5. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
[TBL] [Abstract][Full Text] [Related]
6. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
7. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
8. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death.
de Koning PJ; Kummer JA; de Poot SA; Quadir R; Broekhuizen R; McGettrick AF; Higgins WJ; Devreese B; Worrall DM; Bovenschen N
PLoS One; 2011; 6(8):e22645. PubMed ID: 21857942
[TBL] [Abstract][Full Text] [Related]
9. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Bose A; Baral R
Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
[TBL] [Abstract][Full Text] [Related]
10. Resistance against natural killer cell cytotoxicity: analysis of mechanisms.
Hasenkamp J; Borgerding A; Wulf G; Uhrberg M; Jung W; Dingeldein S; Truemper L; Glass B
Scand J Immunol; 2006 Oct; 64(4):444-9. PubMed ID: 16970688
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood.
Bratke K; Kuepper M; Bade B; Virchow JC; Luttmann W
Eur J Immunol; 2005 Sep; 35(9):2608-16. PubMed ID: 16106370
[TBL] [Abstract][Full Text] [Related]
12. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
13. Targeting and amplification of immune killing of tumor cells by pro-Smac.
Li R; Rüttinger D; Urba W; Fox BA; Hu HM
Int J Cancer; 2004 Mar; 109(1):85-94. PubMed ID: 14735472
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
[TBL] [Abstract][Full Text] [Related]
15. Effect of carbamate pesticides on perforin, granzymes A-B-3/K, and granulysin in human natural killer cells.
Li Q; Kobayashi M; Kawada T
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):403-10. PubMed ID: 25921628
[TBL] [Abstract][Full Text] [Related]
16. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency.
Hirst CE; Buzza MS; Bird CH; Warren HS; Cameron PU; Zhang M; Ashton-Rickardt PG; Bird PI
J Immunol; 2003 Jan; 170(2):805-15. PubMed ID: 12517944
[TBL] [Abstract][Full Text] [Related]
17. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
18. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B.
Gehrmann M; Doss BT; Wagner M; Zettlitz KA; Kontermann RE; Foulds G; Pockley AG; Multhoff G
J Immunol Methods; 2011 Aug; 371(1-2):8-17. PubMed ID: 21723287
[TBL] [Abstract][Full Text] [Related]
19. Granzyme B-induced apoptosis in cancer cells and its regulation (review).
Rousalova I; Krepela E
Int J Oncol; 2010 Dec; 37(6):1361-78. PubMed ID: 21042704
[TBL] [Abstract][Full Text] [Related]
20. Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cell-mediated killing.
Scott GB; Bowles PA; Wilson EB; Meade JL; Low BC; Davison A; Blair GE; Cook GP
Biochem J; 2010 Nov; 431(3):423-31. PubMed ID: 20704564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
